CYP1B1, but not CYP1A1, is downregulated by promoter methylation in colorectal cancers

International Journal of Oncology

Volumn 34, Issue 4, 2009, Pages 1085-1091

  Habano, Wataru ^a   Gamo, Toshie ^a   Sugai, Tamotsu ^a   Otsuka, Koki ^a   Wakabayashi, Go ^a   Ozawa, Shogo ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

CYP1B1; DNA methylation; Gene regulation

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CARCINOGEN; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; HYPOXIA INDUCIBLE FACTOR 1BETA; MESSENGER RNA;

5' UNTRANSLATED REGION; ALLELE; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENE ACTIVATION; GENE SEQUENCE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROMOTER REGION;

ALLELES; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CPG ISLANDS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 ENZYME SYSTEM; DNA METHYLATION; DNA PRIMERS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROMOTER REGIONS, GENETIC; RECEPTORS, ARYL HYDROCARBON; RNA, MESSENGER;

EID: 67649419039     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000235     Document Type: Article

References (35)

1. Jaiswal AK, Gonzalez FJ and Nebert DW: Human dioxininducible cytochrome P1-450: complementary DNA and amino acid sequence. Science 228: 80-83, 1985.
2. Sutter TR, Tang YM, Hayes CL, et al: Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J Biol Chem 269: 13092-13099, 1994.
3. Gonzalez FJ and Gelboin HV: Role of human cytochrome p450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 26: 165-183, 1994.
4. Denison MS, Fisher JM and Whitlock JP Jr: Protein-DNA interaction at recognition sites for the dioxin Ah-receptor complex. J Biol Chem 264: 16478-16482, 1989.
5. Reyes H, Reisz-Porszasz S and Hankinson O: Identification of the Ah receptor nuclear translocation protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science 256: 1193-1195, 1992.
6. Kress S and Greenlee WF: Cell-specific regulation of human CYP1A1 and CYP1B1 genes. Cancer Res 57: 1264-1269, 1997.
7. Murray G, Melvin WT, Greenlee WF and Burke MD: Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu Rev Pharmacol Toxicol 41: 297-316, 2001.
8. Hayes C, Spink D, Spink B, Cao J, Walker N and Sutter T: 17β-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci USA 93: 9776-9781, 1996.
9. Listgarten J, Damaraju S, Poulin B, et al: Predictive models for breast cancer susceptibility from multiple single nucleotide polymorphisms. Clin Cancer Res 10: 2725-2737, 2004.
10. Tanaka Y, Sasaki M, Kaneuchi M, Shiina H, Igawa M and Dahiya R: Polymorphisms of the CYP1B1 gene have higher risk for prostate cancer. Biochem Biophys Res Commun 296: 820-826, 2002.
11. Murray GI, Taylor MC, McFadyen MCE, McKay JA, Greenlee WF, Burke MD and Melvin WT: Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 57: 3026-3031, 1997.
12. Kumarakulasingham M, Rooney PH, Dundas SR, Telfer C, Melvin WT, Curran S and Murray GI: Cytochrome P450 profile of colorectal cancer: identification of markers of prognosis. Clin Cancer Res 11: 3758-3765, 2005.
13. Gibson P, Gill JH, Khan PA, et al: Cytochrome P450 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development. Mol Cancer Ther 2: 527-534, 2003.
14. Bethke L, Webb E, Sellick G, et al: Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk. BMC Cancer 7: 123, 2007.
15. Lund AH and van Lohuizen M: Epigenetics and cancer. Genes Dev 18: 2315-2335, 2004.
16. Gagnon J-F, Bernard O, Villeneuve L, Têtu B and Guillemette C: Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer. Clin Cancer Res 12: 1850-1858, 2006.
17. Tokizane T, Shiina H, Igawa M, et al: Cytochrome P4501B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin Cancer Res 11: 5793-5801, 2005.
18. Habano W, Sugai T, Nakamura S and Yoshida T: A novel method for gene analysis of colorectal carcinomas using a crypt isolation technique. Lab Invest 74: 933-940, 1996.
19. Habano W, Sugai T, Jiao YF and Nakamura S: Novel approach for detecting global epigenetic alterations associated with tumor cell aneuploidy. Int J Cancer 121: 1487-1493, 2007.
20. Xiong Z and Laird PW: COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 25: 2532-2534, 1997.
21. Chang H, Chang LW, Cheng Y-H, Tsai W-T, Tsai M-X and Lin P: Preferential induction of CYP1A1 and CYP1B1 in CCSP-positive cells. Toxicol Sci 89: 205-213, 2006.
22. Kress S, Reichert J and Schwarz M: Functional analysis of the human cytochrome P450A1 (CYP1A1) gene enhancer. Eur J Biochem 258: 803-812, 1998.
23. Wo Y-YP, Stewart J and Greenlee WF: Functional analysis of the promoter for the human CYP1B1 gene. J Biol Chem 272: 26702-26707, 1997.
24. Shehin SE, Stephenson RO and Greenlee WF: Transcriptional regulation of the human CYP1B1 gene: Evidence for involvement of an aryl hydrocarbon receptor response element in constitutive expression. J Biol Chem 275: 6770-6776, 2000.
25. Tsuchiya Y, Nakajima M and Yokoi T: Critical enhancer region to which AhR/ARNT and Sp1 bind in the human CYP1B1 gene. J Biochem 133: 583-592, 2003.
26. Chang JT, Chang H, Chen PH, Lin S-L and Lin P: Requirement of aryl hydrocarbon receptor overexpression for CYP1B1 upregulation and cell growth in human lung adenocarcinomas. Clin Cancer Res 13: 38-45, 2007.
27. Okino ST, Pookot D, Li L-C, et al: Epigenetic inactivation of the dioxin-responsive cytochrome P4501A1 gene in human prostate cancer. Cancer Res 15: 7420-7428, 2006.
28. Kang GH, Lee S, Cho NY, et al: DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis. Lab Invest 88: 161-170, 2008.
29. Tsuchiya Y, Nakajima M, Takagi S, Taniya T and Yokoi T: MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res 66: 9090-9098, 2006.
30. Chesire DR, Dunn TA, Ewing CM, Luo J and Isaacs WB: Identification of aryl hydrocarbon receptor as a putative wnt/β-catenin pathway target gene in prostate cancer cells. Cancer Res 64: 2523-2533, 2004.
31. Ciolino HP, Bass SE, MacDonald CJ, Cheng RYS and Yeh GC: Sulindac and its metabolites induce carcinogen metabolizing enzymes in human colon cancer cells. Int J Cancer 122: 990-998, 2008.
32. Ando Y, Saka H, Ando M, et al: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60: 6921-6926, 2000.
33. Iyer L, Das S, Janisch L, et al: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2: 43-47, 2002.
34. Rouits E, Boisdron-Celle M, Dumont A, Guérin O, Morel A and Gamelin E: Relevance of different UGT1A1 polymorphisms in irinotecan-incuced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 10: 5151-5159, 2004.
35. Sai K, Saito Y, Sakamoto H, et al: Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients. Cancer Lett 261: 165-171, 2008.